DE69630802D1 - Meiose regulierende verbindungen. - Google Patents

Meiose regulierende verbindungen.

Info

Publication number
DE69630802D1
DE69630802D1 DE69630802T DE69630802T DE69630802D1 DE 69630802 D1 DE69630802 D1 DE 69630802D1 DE 69630802 T DE69630802 T DE 69630802T DE 69630802 T DE69630802 T DE 69630802T DE 69630802 D1 DE69630802 D1 DE 69630802D1
Authority
DE
Germany
Prior art keywords
meiose
regulatory links
regulatory
links
meiose regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69630802T
Other languages
English (en)
Other versions
DE69630802T2 (de
Inventor
Christian Groenvald
Peter Faarup
Erling Guddal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69630802D1 publication Critical patent/DE69630802D1/de
Publication of DE69630802T2 publication Critical patent/DE69630802T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69630802T 1995-06-23 1996-06-21 Meiose regulierende verbindungen. Expired - Fee Related DE69630802T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK72895 1995-06-23
DK73095 1995-06-23
DK73095 1995-06-23
DK72895 1995-06-23
DK146195 1995-12-22
DK146195 1995-12-22
PCT/DK1996/000273 WO1997000884A1 (en) 1995-06-23 1996-06-21 Meiosis regulating compounds

Publications (2)

Publication Number Publication Date
DE69630802D1 true DE69630802D1 (de) 2003-12-24
DE69630802T2 DE69630802T2 (de) 2004-08-12

Family

ID=27220892

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630802T Expired - Fee Related DE69630802T2 (de) 1995-06-23 1996-06-21 Meiose regulierende verbindungen.

Country Status (18)

Country Link
EP (1) EP0857173B1 (de)
JP (1) JPH11507929A (de)
KR (1) KR19990028366A (de)
CN (1) CN1191543A (de)
AR (1) AR003441A1 (de)
AT (1) ATE254628T1 (de)
AU (1) AU718246B2 (de)
BR (1) BR9608968A (de)
CA (1) CA2224866A1 (de)
CZ (1) CZ408097A3 (de)
DE (1) DE69630802T2 (de)
HU (1) HUP9900454A3 (de)
IL (1) IL122609A0 (de)
NO (1) NO314231B1 (de)
PL (1) PL185622B1 (de)
RU (1) RU2182909C2 (de)
TW (1) TW474943B (de)
WO (1) WO1997000884A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE229032T1 (de) 1997-05-16 2002-12-15 Akzo Nobel Nv 20-aralkyl-5,alpha,-pregnan derivate
AU8535398A (en) 1997-06-04 1998-12-21 Akzo Nobel N.V. 17beta-allyloxy(thio)alkyl-androstane derivatives for the modulation of meiosis
ATE220686T1 (de) * 1997-12-18 2002-08-15 Akzo Nobel Nv 17beta-aryl(arylmethyl)oxy(thio)alkyl- androstanderivative
EP0957108A1 (de) * 1998-05-14 1999-11-17 Schering Aktiengesellschaft Ungesättigte Cholestan-derivate zur Regulierung von Meiose und pharmazeutische Präparate davon
IL139241A0 (en) * 1998-05-13 2001-11-25 Novo Nordisk As Meiosis regulating compounds
KR20010053031A (ko) * 1998-06-19 2001-06-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
AU759344B2 (en) * 1998-12-11 2003-04-10 Akzo Nobel N.V. 22S-hydroxycholesta-8, 14-diene derivatives with meiosis regulating activity
WO2000036132A1 (en) * 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
IL143735A0 (en) * 1999-02-10 2002-04-21 Schering Ag Unsaturated cholestane derivatives and their use for the preparation of meiosis regulating medicaments
ATE361091T1 (de) 1999-02-24 2007-05-15 Novo Nordisk As Behandlung von unfruchtbarkeit
JP2002537349A (ja) * 1999-02-24 2002-11-05 ノボ ノルディスク アクティーゼルスカブ 不妊症の治療
BR0014058A (pt) 1999-09-16 2004-03-30 Novo Nordisk As Produto sólido, composição, solução aquosa de 4,4-dimetil-5a-colesta-8,14,24-triene-3(beta) -ol, e, dispositivo tendo uma concavidade
EP1127890A1 (de) 2000-02-22 2001-08-29 Schering Aktiengesellschaft Steroid Derivate mit einem an Ring A des Steroidgerüstes kondensierten Ring zur Regulierung der Meiose
CA2399036A1 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate
EP1245572A1 (de) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol-Verbindungen, ihre Verwendung zur Herstellung Meiose-regulierender Medikamenten und ein Vefahren zu ihrer Herstellung
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CN102258004B (zh) * 2010-05-27 2013-07-17 中国科学院动物研究所 一种体外保存/培养***以抑制***生发泡破裂的方法
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
HRP20220978T1 (hr) 2013-12-24 2022-11-11 Virginia Commonwealth University Upotreba oksidiranih kolesterol sulfata (ocs) za liječenje disfunkcije bubrega
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EA024619B1 (ru) * 2014-11-21 2016-10-31 Эльвин Гаджи оглы Керимли ФРАКСИНОСТЕРИН - 24β-ЭТИЛХОЛЕСТА-20-КАРБОКСИ-6(7),8(9)-ДИЕН 3β-ОЛА И ЕГО ПРОИЗВОДНОЕ
WO2017007832A1 (en) 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3812392A1 (de) 2015-07-06 2021-04-28 Sage Therapeutics, Inc. Oxysterole und verfahren zur verwendung davon
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3481846T3 (pl) 2016-07-07 2021-12-20 Sage Therapeutics, Inc. 11-podstawione 24-hydroksysterole do stosowania w leczeniu stanów związanych z NMDA
HRP20220932T1 (hr) 2016-08-02 2022-10-28 Virginia Commonwealth University Sastavi koji sadrže 5-kolesten-3, 25-diol, 3-sulfat (25hc3s) ili njegovu farmaceutski prihvatljivu sol i barem jedan ciklički oligosaharid
US11149056B2 (en) 2016-09-30 2021-10-19 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
ES2968140T3 (es) 2016-10-18 2024-05-08 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
CN112430251A (zh) * 2020-11-23 2021-03-02 广州瀚信通信科技股份有限公司 一种治疗白内障的化合物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols

Also Published As

Publication number Publication date
CZ408097A3 (cs) 1998-06-17
DE69630802T2 (de) 2004-08-12
WO1997000884A1 (en) 1997-01-09
EP0857173B1 (de) 2003-11-19
JPH11507929A (ja) 1999-07-13
TW474943B (en) 2002-02-01
NO314231B1 (no) 2003-02-17
AU718246B2 (en) 2000-04-13
PL324219A1 (en) 1998-05-11
AR003441A1 (es) 1998-08-05
NO976044L (no) 1998-02-20
RU2182909C2 (ru) 2002-05-27
CN1191543A (zh) 1998-08-26
HUP9900454A3 (en) 1999-11-29
ATE254628T1 (de) 2003-12-15
KR19990028366A (ko) 1999-04-15
MX9800123A (es) 1998-03-29
PL185622B1 (pl) 2003-06-30
HUP9900454A2 (hu) 1999-06-28
EP0857173A1 (de) 1998-08-12
NO976044D0 (no) 1997-12-22
AU6122796A (en) 1997-01-22
CA2224866A1 (en) 1997-01-09
BR9608968A (pt) 1999-06-29
IL122609A0 (en) 1998-08-16

Similar Documents

Publication Publication Date Title
DE69630802D1 (de) Meiose regulierende verbindungen.
DE69636353D1 (de) Datenübetragungsvorrichtung.
NL1004863A1 (nl) 5-Amino-4-ethylsulfinyl-1-arylpyrazolen.
NL300214I1 (nl) Chinazolinederivaten.
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
TR199600883A2 (tr) Pürin-6-on türevleri.
TR199600715A2 (tr) Kefalosforin türevleri.
NL1000095C2 (nl) Rolhor.
DK0874814T3 (da) 25-hydroxy-16-en-26,27-bishomo-cholecalciferoler
TR199600064A2 (tr) 4-amino-benzoilguanidin-türevleri.
ES1032571Y (es) Gafa,
ES1031606Y (es) Estuche.
ES1031424Y (es) Estuche.
TR199501236A2 (tr) Halka bicimindeki birarada tutma vasitasi.
ES1030207Y (es) Cinturon.
ES1031411Y (es) Embalaje.
IT1276501B1 (it) Via tranviaria.
ES1030500Y (es) Braga-compresa monouso.
ES1032657Y (es) Banderilla.
ES1029950Y (es) Interruptor-conmutador.
ES1030124Y (es) Bloc-pizarra.
ES1030262Y (es) Porta-objetos.
IT240242Y1 (it) Pentola-colapasta-zuppiera.
ES1030760Y (es) Tocado-postizo.
ES1031132Y (es) Prensa-latas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee